Figure 5
ADTM inhibits activation of αIIbβ3 integrin and disrupts the ERp57/αIIbβ3 complex on platelets.
Representative flow cytometry histogram (a) and the quantification of the data (b) show that ADTM inhibits PAC-1 binding to ADP-activated platelets. (c) ADTM disrupts the ERp57/αIIbβ3 complex. Whole blood was treated with DMSO (0.1%) as a control or 100 μM ADTM for 5 min at 37 °C. After that the platelets were activated using ADP (10 μM). Platelet lysates were prepared for immunoprecipitation (IP) and probed with anti-ERp57 antibody for immunoblot analysis (IB). The precipitates were also blotted with anti-αIIbβ3 antibody to ensure that equal amounts of αIIbβ3 were pulled down under each condition. #P < 0.01 compared with the control group, *P < 0.01 compared with the ADP group. Data are representative of three independent experiments.
